Recent Finacing
Recent Raise
Cytheris develops recombinant interleukin‑7 (CYT107) to accelerate T‑cell recovery, conducting international clinical trials in HIV, HBV, HCV, idiopathic CD4 lymphocytopenia and cancer, with a U.S. subsidiary in Rockville.
Focus Areas
Recent Investors
Funding round
Investors
